Groenendyk et al. discovered that genetic inactivation of SLC2A5 (GLUT5) significantly inhibits cancer cell migration by modulating mitochondrial function, indicating that GLUT5 expression directly contributes to tumor metastasis risk and thus represents a promising therapeutic target 138. The gene discussed is SLC2A5; the disease is neoplasm.